When patients’ own autologous whole tumor cells are engineered to co-express GM-CSF and a shRNA against furin, subsequently irradiated, and delivered to ovarian cancer patients during periods of remission, blood samples from treated patients have increased levels of IFNγ, and treated patients experience a significant survival benefit [72]. This evidence concerns the gene FURIN and ovarian cancer.